Evaluating the Effects of Heat-Clearing Traditional Chinese Medicine in Stable Bronchiectasis by a Series of N-of-1 Trials

Suna Zi, Haiyin Huang, Peilan Yang, Minhua Xu, Yingen Wu, Zhenwei Wang, Fei Ge, Xinlin Chen, Suna Zi, Haiyin Huang, Peilan Yang, Minhua Xu, Yingen Wu, Zhenwei Wang, Fei Ge, Xinlin Chen

Abstract

Purpose: The purpose of this study is to study the effects of heat-clearing Traditional Chinese Medicine (TCM) in the stable stage of bronchiectasis via N-of-1 trials.

Methods: The N-of-1 trials in this study were randomized and double-blinded with crossover comparisons consisting of three pairs. Each pair was of two 4-week periods. Each patient took the individualized decoction in the experimental period and the individualized decoction was removed of heat-clearing drugs, mainly including heat-clearing and detoxifying drugs, in the control period for three weeks. After three weeks, the patients stopped taking the decoction for one week. The primary outcome was from patients' self-reporting symptoms scores on a 1-7-point Likert scale. Mixed-effects models were used to conduct statistical analysis on these N-of-1 trials.

Results: Of the 21 patients enrolled, 15 completed three pairs of N-of-1 trials (71.43%). (1) Seen from the individual level, no statistical difference between the experimental decoction and the control (P > 0.05) was observed. However, 5 patients found better decoctions according to the clinical criteria. (2) As revealed by the group data of all the N-of-1 trials, the control was better than the individualized decoction in terms of symptom scores on the Likert scale (1.94 ± 0.69 versus 2.08 ± 0.68, P = 0.04, mean difference, and 95% CI: 0.19 (0.01, 0.37)) and on CAT scores (13.66 ± 6.57 versus 13.95 ± 6.97, P = 0.04, mean difference, and 95% CI: 0.86 (0.042, 1.67)), but such differences were not clinically significant. The other outcomes, such as Likert scale score of respiratory symptoms and 24-hour sputum volume, showed no statistical difference.

Conclusion: The experimental design of this study can make the TCM individualized treatment fully play its role and can detect the individualized tendencies according to the severity of phlegm and heat in some subjects. With the intermittent use or reduced use of heat-clearing drugs, most of the subjects, at the group level, enrolled in the series of N-of-1 trials may improve the symptoms and quality of life while saving the cost of TCM and reducing the potential side effects of heat-clearing TCM. This trial is registered with clinicaltrials.goc (NCT03147443).

Conflict of interest statement

All the authors declare that there are no conflicts of interest with respect to the publication of this paper.

Copyright © 2022 Suna Zi et al.

Figures

Figure 1
Figure 1
The flow chart of the N-of-1 trial of an individual patient in this study.
Figure 2
Figure 2
The flow chart of the whole process including the number of cases recruited, enrolled, and completed in this study.

References

    1. Polverino E., Goeminne P. C., McDonnell M. J., et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal . 2017;50(3) doi: 10.1183/13993003.00629-2017.1700629
    1. Guan W. J., Gao Y. H., Yuan J. J., Chen R. C., Zhong N. S. Additional important research priorities for bronchiectasis in China. European Respiratory Journal . 2017;49(1) doi: 10.1183/13993003.01747-2016.1601747
    1. Lin J. L., Xu J. F., Qu J. M. Bronchiectasis in China. Annals of the American Thoracic Society . 2016;13(5):609–616. doi: 10.1513/annalsats.201511-740ps.
    1. Chandrasekaran R., Mac Aogáin M., Chalmers J. D., Elborn S. J., Chotirmall S. H. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulmonary Medicine . 2018;18(1):p. 83. doi: 10.1186/s12890-018-0638-0.
    1. Huang H. Y., Yang P. L., Tang J. Long term effect of the treatment method of strengthening vital Qi, transforming Phlegm and clearing heat for 46 cases of bronchiectasis. Journal of Traditional Chinese Medicine . 2012;53(10):848–852.
    1. Zhang H., Li X., Ni W. Study on the pattern of TCM syndrome differentiation of bronchiectasis. Shanghai Journal of Traditional Chinese Medicine . 2005;51(1):16–18.
    1. Pan W. C., Shi S. F. Clinical research progress of TCM treatment of bronchiectasis. Jiangxi Chinese Medicine . 2009;40(1):75–77.
    1. Wu Y. G., Tang B. Q. Thoughts and Experience of TCM Diagnosis and Treatment of Lung Diseases in Wu Yingen . Shanghai, China: Shanghai Science and Technology Press; 2016. p. p. 180.
    1. He M. T., Tian Z. J. Professor tian zhengjian’s experience in the treatment of bronchiectasis. Inner Mongolia traditional Chinese medicine . 2013;32(3):77–78.
    1. Richardson H., Dicker A. J., Barclay H., Chalmers J. D. The microbiome in bronchiectasis. European Respiratory Review . 2019;28(153) doi: 10.1183/16000617.0048-2019.190048
    1. Zhou Y. Y., Cheng Q., Liu K., et al. The antibacterial activity of traditional Chinese medicinal materials of heatclearing and detoxifying in China Pharmacopeia 2015. Chinese Journal of Antibiotics . 2018;43(10):1161–1167.
    1. Pang Z. Y., Wu X. L., Hua Y. The bacteriostatic effect of four kinds of traditional Chinese herbal medicines on thirty strains of exten sively drug-resistant Pseudomonas aeruginosa. China Licensed Pharmacist . 2015;12(2):25–27+45. doi: 10.4314/ajtcam.v12i6.3.
    1. Huang H. Y., Yang P. L., Wang J., et al. Investigation into the individualized treatment of traditional Chinese medicine through a series of N-of-1 trials. Evidence-Based Complementary and Alternative Medicine . 2018;2018:11. doi: 10.1155/2018/5813767.5813767
    1. Zucker D. R., Ruthazer R., Schmid C. H. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. Journal of Clinical Epidemiology . 2010;63(12):1312–1323. doi: 10.1016/j.jclinepi.2010.04.020.
    1. Chen Y. M., Deng J. M., Wen Y., et al. Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials. Trials . 2020;21(1):p. 396. doi: 10.1186/s13063-020-04315-0.
    1. Guyatt G., Rennie D. Users’Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice . Chicago, IL, USA: American Medical Association Press; 2002. pp. 3–11.
    1. Guyatt G. H., Keller J. L., Jaeschkeetal R. Then-of-1 randomized controlled trial: clinical usefulness. Annals of Internal Medicine . 1990;112(4):293–299. doi: 10.7326/0003-4819-112-4-293.
    1. Huang H. Y., Yang P. L., Xue J. J., et al. Evaluating the individualized treatment of traditional Chinese medicine: a pilot study of N-of-1 Trials. Evidence-Based Complementary and Alternative Medicine . 2014;2014:10. doi: 10.1155/2014/148730.148730
    1. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2 . Oxford, UK: Oxford Centre for Evidence-Based Medicine; 2011. .
    1. Expert Consensus Writing Group on Diagnosis and Treatment of Bronchiectasis. Expert consensus on diagnosis and treatment of bronchiectasis. Chinese journal of tuberculosis and respiratory . 2013;36(8):563–566.
    1. Pasteur M. C., Bilton D., Hill A. T. British thoracic society guideline for non-CF bronchiectasis. Thorax . 2010;65(Suppl l):i1–i58. doi: 10.1136/thx.2010.136119.
    1. State administration of traditional Chinese medicine. Criteria for Diagnosis and Efficacy of TCM Diseases . Nanjing, China: Nanjing University Press; 1994. p. p. 5.
    1. Lu L. The comparative study of traditional and modern boil medicine methods. China Medicine and Pharmacy . 2012;2(18):45–46.
    1. Lee S., Lee J. S., Song J. W., et al. validity and reliability of CAT and dyspnea-12 in bronchiectasis and tuberculous destroyed lung. Tuberculosis and Respiratory Diseases . 2012;72(6):467–474. doi: 10.4046/trd.2012.72.6.467.
    1. Dodd J. W., Hogg L., Nolan J., et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax . 2011;66(5):425–429. doi: 10.1136/thx.2010.156372.
    1. Zheng X. Y. Guiding Principles for Clinical Research of New Chinese Medicine . Beijing, China: China Medical Science and Technology Press; 2002. pp. 56–64.
    1. Chen K. W., Chow S. C., Li G. A note on sample size determination for bioequivalence studies with higher-order crossover designs. Journal of Pharmacokinetics and Biopharmaceutics . 1997;25(6):753–765.
    1. Chow S. C., Shao J., Wang H. Sample Size Calculations in Clinical Research . New York, NY, USA: Marcel Dekker; 2003.
    1. Guyatt G., Sackett D., Adachi J. A clinician’s guide for conduction randomized trials in individual patients. Canadian Medical Association Journal . 1988;139:497–503.
    1. Li J., Niu J., Yang M., et al. Using single-patient (n-of-1) trials to determine effectiveness of traditional Chinese medicine on chemotherapy-induced leukopenia in gastric cancer: a feasibility study. Annals of Translational Medicine . 2019;7(6):p. 124. doi: 10.21037/atm.2019.02.03.
    1. Jiao Z. N., Zhao M. M., Zhang Y., et al. Single case randomized controlled research of Modified Huangqi Chifeng Decoction in the treatment of proteinuria due to IgA nephropathy. China Medical News . 2018;15(1):95–98.
    1. Ming Y., Xu C. L., Tao J., et al. A single case randomized controlled experiment on syndrome of kidney Yang deficiency of pure red cell aplastic anemia by regulating the function of liver-spleen-kidney. Chinese Medicine Modern Distance Education of China . 2019;17(5):46–49.
    1. Dai L. L., Meng P., Dou H. H., et al. Clinical observation on the effects of jianpi quzhuo xiaoji granules in the treatment of chemotherapy-associated diarrhea of advanced colorectal cancer. World Chinese Medicine . 2019;14(4):958–965.
    1. Huang L. L., Zhao X. F., Guo L. Z. Modified liangxue huayu recipein the treatment of essential thrombocytosis: a n of one trial. Journal of Traditional Chinese Medicine . 2019;60(8):680–683.
    1. Liu Y., Huang B., Chen S., et al. N of one randomized controlled double-blind trial of liuwei dihuang capsule in the treatment of liver and kidney Yin deficiency syndrome. Journal of Traditional Chinese Medicine . 2018;59(11):947–951.
    1. Xie Z. J., Wen C. P., Fan Y. S. Discussion on quality control of randomized, double-blind and placebo controlled clinical trial of Chinese medicine. China Journal of Traditional Chinese Medicine and Pharmacy . 2012;27(6):1479–1481.
    1. Zhang Y. B., Wang L. H., Hong G. X. Hong Guangxiang,s experience in treating bronchiectasis based on“pulmonary treatment not far from warming”theory. Shanghai Journal of Traditional Chinese Medicine . 2013;47(2):14–19.
    1. Shamseer L., Sampson M., Bukutu C., et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. BMJ . 2015;350(may14 15) doi: 10.1136/bmj.h1793.h1793
    1. Senior H. E., Mitchell G. K., Nikles J., et al. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. BMC Palliative Care . 2013;12(1):17–6. doi: 10.1186/1472-684X-12-17.
    1. Zhai J. B., Li J., Shang H. C. Brief introduction of Bayesian N-of-1 trials. Chinese Journal of Evidence-Based Medicine . 2017;17(7):848–851.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren